Blood and lymphatic system disorders – page 101

Study Comparing ARI-0001 and Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Study on the Effectiveness and Safety of Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions

Study on the Effectiveness and Safety of Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions

Study on the Safety and Effectiveness of Azacitidine and Venetoclax for Untreated Higher-Risk Myelodysplastic Syndromes Not Eligible for Transplant

Study on the Safety and Effectiveness of Azacitidine and Venetoclax for Untreated Higher-Risk Myelodysplastic Syndromes Not Eligible for Transplant

Study on the Risk of Tumor Lysis Syndrome in Adults with Untreated Chronic Lymphocytic Leukemia Using Venetoclax, Obinutuzumab, or Acalabrutinib

Study on the Risk of Tumor Lysis Syndrome in Adults with Untreated Chronic Lymphocytic Leukemia Using Venetoclax, Obinutuzumab, or Acalabrutinib

Study of Pacritinib for Patients with Severe Thrombocytopenia in Myelofibrosis Conditions

Study of Pacritinib for Patients with Severe Thrombocytopenia in Myelofibrosis Conditions

Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma

Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma